Why There Are No Settlements Yet — And When That May Change
Pharmaceutical defendants do not generally settle until litigation has progressed to a point where trial risk is clear. In the Tylenol autism litigation, the federal MDL was dismissed in August 2024 without any bellwether trials — meaning no jury has yet evaluated the evidence. The Second Circuit appeal, pending since late 2024, must be resolved before the federal case path is clear. State court cases in California and Illinois are in earlier stages. Settlement discussions typically begin in earnest after: (a) plaintiffs survive Daubert or Frye challenges to their causation experts; (b) at least one bellwether case goes to verdict; or (c) the overall litigation scale makes global resolution more attractive than continued defense costs. One or more of these triggering events may occur in 2026, making the current period the best time to evaluate and preserve your claim before any resolution is structured.
Projected Value Ranges by Diagnosis
Based on comparable pharmaceutical mass torts and published neurodevelopmental cost-of-care data, here are projected ranges if the litigation reaches resolution: ADHD-only claims — $75,000 to $250,000 depending on severity and documentation. Level 1 ASD or combined ASD+ADHD with moderate impact — $150,000 to $400,000. Level 2 ASD requiring substantial support — $300,000 to $750,000. Level 3 ASD requiring very substantial support with lifetime care documentation — $500,000 to $1,500,000 or more. These are projections based on comparable cases, not guarantees. The actual resolution values will depend entirely on the litigation outcome, which remains uncertain pending the Second Circuit ruling and state court developments.
What Drives Case Value Up
Factors that increase the value of an individual claim: higher ASD severity level (levels 2 and 3 have higher lifetime care cost documentation); lifetime care cost analysis prepared by a life care planner; strong prenatal exposure documentation (pharmacy records, OB records noting acetaminophen use); neuropsychological testing showing significant cognitive and adaptive behavior impact; early and consistent treatment records demonstrating the extent of functional impairment; economic expert analysis of lifetime earning capacity loss; and claims in plaintiff-favorable jurisdictions (California, Illinois) where Frye standard applies. Claims with all of these factors present the strongest individual valuations.
Frequently Asked Questions
Related Pages
Tylenol Liver Damage Lawsuit
Acetaminophen — the active ingredient in Tylenol — is the leading cause of acute liver failure in the United States, responsible for approximately 56,000 emergency room visits, 26,000 hospitalizations, and nearly 500 deaths each year. Lawsuits allege that McNeil Consumer Healthcare and parent company Johnson & Johnson failed to adequately warn consumers about the narrow margin between a therapeutic dose and a potentially fatal overdose. Even doses only slightly above the recommended amount, especially when combined with alcohol use or taken across multiple acetaminophen-containing products, can cause catastrophic liver damage. If you or a loved one suffered acute liver failure, liver transplant, or death linked to acetaminophen use, you may be eligible for compensation. These liver damage claims are separate from the Tylenol autism/ADHD litigation — they involve direct injury to the person who took the medication.
Learn moreLearn moreLearn moreLearn moreLearn moreLearn moreTylenol Autism Lawsuit Lawsuit
Acetaminophen — sold under the brand name Tylenol by Kenvue (formerly Johnson & Johnson) and as dozens of store-brand generics by Walmart, CVS, Walgreens, Target, Costco, Meijer, and others — was the most commonly used pain reliever during pregnancy in the United States for decades. Starting with a landmark 2018 American Journal of Epidemiology meta-analysis of 130,000 mother-child pairs, and culminating in a 2021 consensus statement signed by 91 scientists published in Nature Reviews Endocrinology, accumulating evidence linked prolonged prenatal acetaminophen exposure to significantly elevated risks of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). The federal multidistrict litigation, MDL-3043 (In re Acetaminophen — ASD/ADHD Products Liability Litigation) in the Southern District of New York, was dismissed in August 2024 after Judge Denise L. Cote excluded all plaintiffs' general causation experts under the Daubert standard. Critically, the Second Circuit Court of Appeals heard oral arguments on November 17, 2025 — and two of the three judges on the panel openly questioned whether Judge Cote acted too aggressively in excluding the expert testimony. A reversal by the Second Circuit could reinstate thousands of federal cases. Separately, California state courts (Alameda County) and Illinois state courts (St. Clair, Madison, and Cook counties) have active acetaminophen-autism cases proceeding under the Frye admissibility standard, which does not apply the same gatekeeping test that closed the federal MDL. Store-brand acetaminophen users have the same legal claims as Tylenol brand users — the failure-to-warn theory applies equally to Walmart's Equate brand, CVS Health brand, Walgreens brand, Costco Kirkland brand, and all other private-label acetaminophen products.
View full case overview